Metoclopramide Noridem

Metoclopramide, the active ingredient in Metoclopramide Noridem, is a dopamine antagonist presented as an injectable solution for intramuscular and intravenous use. It treats nausea and vomiting, gastroparesis, migraine‑associated nausea and postoperative nausea and vomiting in adult patients.

GNH USA supplies Metoclopramide Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to EU and other markets. Customers benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical support throughout the procurement process.

Metoclopramide is used to manage conditions related to nausea, vomiting and delayed gastric emptying.

- Nausea and vomiting: reduces episodes by blocking dopamine receptors in the chemoreceptor trigger zone. - Gastroparesis: improves gastric motility and accelerates stomach emptying. - Migraine‑associated nausea: alleviates nausea accompanying migraine attacks. - Postoperative nausea and vomiting: prevents or treats nausea after surgery.

Metoclopramide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or agitation - Diarrhea - Headache - Dry mouth

Serious or Rare Side Effects: - Extrapyramidal reactions (dystonia, akathisia) - Tardive dyskinesia with prolonged use - Neuroleptic malignant syndrome - Severe hypotension or cardiovascular collapse - Anaphylactic or severe allergic reaction - Depression, suicidal thoughts or other psychiatric changes

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for known risks.

- Assess renal function: adjust use in severe renal impairment. - Monitor for extrapyramidal symptoms: observe for muscle rigidity or involuntary movements. - Avoid in patients with known hypersensitivity to metoclopramide. - Use caution in patients with depression, Parkinson disease, or seizure disorders. - Limit duration: avoid prolonged use beyond 12 days to reduce risk of tardive dyskinesia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metoclopramide can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase metoclopramide plasma concentrations. - Other dopamine antagonists (e.g., antipsychotics): additive central nervous system effects.

Moderate Interactions (Monitor Closely): - Opioids: may enhance antiemetic effect but increase sedation. - Anticholinergic agents: may reduce pro‑kinetic efficacy and increase constipation.